Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Related Citations for PubMed (Select 6105246)

1.

Reappraisal of plateau phase in myeloma.

Durie BG, Russell DH, Salmon SE.

Lancet. 1980 Jul 12;2(8185):65-8.

PMID:
6105246
2.

Myeloma protein kinetics following chemotherapy.

McLaughlin P, Alexanian R.

Blood. 1982 Oct;60(4):851-5.

3.

Multiple myeloma without initial paraproteins.

Kim I, Harley JB, Weksler B.

Am J Med Sci. 1972 Oct;264(4):267-75. No abstract available.

PMID:
4630526
4.

Acute phase reactants and clinical stages in multiple myeloma.

San Miguel J, Vicente V, Battle J, Hernandez F, Lopez Borrasca A.

Neoplasma. 1981;28(3):333-8.

PMID:
7290260
6.

Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria.

Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Lal R, Singhal S, Mehta J, Horton C, Treleaven J.

Bone Marrow Transplant. 2001 Jul;28(1):29-37.

7.
8.

An unusual case of Bence Jones myeloma with extremely low levels of monoclonal immunoglobulin.

Ozaki M, Yamanaka H.

Oral Surg Oral Med Oral Pathol. 1986 May;61(5):498-503.

PMID:
3086787
9.

Correlation of abnormal immunoglobulin with clinical features of myeloma.

[No authors listed]

Arch Intern Med. 1975 Jan;135(1):46-52.

PMID:
1111470
10.

Cytology of myeloma cells.

Hayhoe FG, Neuman Z.

J Clin Pathol. 1976 Oct;29(10):916-22.

11.

Patterns of amyloidosis and their association with plasma-cell dyscrasia, monoclonal immunoglobulins and Bence-Jones proteins.

Isobe T, Osserman EF.

N Engl J Med. 1974 Feb 28;290(9):473-7. No abstract available.

PMID:
4204196
12.

Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy.

Boccadoro M, Gavarotti P, Fossati G, Pileri A, Marmont F, Neretto G, Gallamini A, Volta C, Tribalto M, Testa MG, et al.

Br J Haematol. 1984 Dec;58(4):689-96.

PMID:
6518137
13.

Whole bone marrow irradiation for the treatment of multiple myeloma.

Coleman M, Saletan S, Wolf D, Nisce L, Wasser J, McIntyre OR, Tulloh M.

Cancer. 1982 Apr 1;49(7):1328-33.

PMID:
7037161
14.

Treatment of multiple myeloma with natural alpha-interferon.

Mellstedt H.

Hematol Oncol. 1988 Apr-Jun;6(2):187-92. No abstract available.

PMID:
3292377
15.

Antitumor activity of thalidomide in refractory multiple myeloma.

Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B.

N Engl J Med. 1999 Nov 18;341(21):1565-71. Erratum in: N Engl J Med 2000 Feb 3;342(5):364.

16.
17.

[Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].

Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P.

Srp Arh Celok Lek. 1996 Nov-Dec;124(11-12):292-6. Serbian.

PMID:
9132962
18.

Clinical classification of plasma cell myeloma.

Conklin R, Alexanian R.

Arch Intern Med. 1975 Jan;135(1):139-43.

PMID:
1111462
19.

The incidence and possible relevance of Bence-Jones protein in the sera of patients with multiple myeloma.

Sinclair D, Dagg JH, Smith JG, Stott DI.

Br J Haematol. 1986 Apr;62(4):689-94.

PMID:
3964561
20.

[Renal disease in myeloma. Role of the tumor cell mass (author's transl)].

San Miguel J, Batlle J, Alberca I, Moraleda JM, López Borrasca A.

Med Clin (Barc). 1981 Apr 25;76(8):347-9. Spanish.

PMID:
7253752
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk